Literature DB >> 16117832

Does age acquired immunity confer selective protection to common serotypes of Campylobacter jejuni?

Gordon Miller1, Geoff M Dunn, Thomas M S Reid, Iain D Ogden, Norval J C Strachan.   

Abstract

BACKGROUND: Campylobacter infection is a major cause of bacterial gastrointestinal disease. Exposure to Campylobacter is known to produce an immune response in humans that can prevent future symptomatic infections. Further, studies of the general population have shown that seroprevalence to Campylobacter increases with age.
METHODS: A large collection of serotyped Campylobacter isolates, obtained from human clinical faecal samples, were analysed by comparing the ratio of uncommon to common serotypes by different age groups, using chi2 tests.
RESULTS: We have identified that older age groups, as well as having generally lower incidence, are significantly less likely to be infected by the more common serotypes.
CONCLUSION: These results are indicative of acquired immunity, however, further studies are needed to rule out the confounding effects of the variations in exposure pathways experienced by different age groups.

Entities:  

Mesh:

Year:  2005        PMID: 16117832      PMCID: PMC1208888          DOI: 10.1186/1471-2334-5-66

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Background

Campylobacter is the greatest cause of human bacterial gastroenteritis in the developed world [1], with more than 50,000 cases reported in the UK alone each year [2]. However, due to under-reporting, it is believed that the true number of cases is around eight times this [2], suggesting humans are infected on average at least once during their lifetime. Symptoms of campylobacteriosis include fever, abdominal cramp, and bloody diarrhoea, which can last for approximately seven days after infection, with one in a 1000 cases leading to the more serious neurological disease, Guillain-Barré syndrome [3]. Approximately 90% of Campylobacter infections are C. jejuni, while the remainder are predominantly C. coli [4]. A variety of typing techniques have been used to subtype these species, including phenotypic Penner heat stable antigen serotyping, genotypic PFGE, AFLP and MLST, which have demonstrated high variability in the genome. Human seroprevalence studies of C. jejuni specific antigens have shown that IgG, IgM, and IgA antibodies are produced during infection [5,6]. The IgM and IgA antibody levels quickly decrease after infection, however, the IgG antibodies can remain elevated for months or years afterwards [5]. A recent study of seroprevalence in Danish adults looked at IgG antibodies in a sample of 1112 people from Copenhagen [7]. It was found that the percentage of people with C.jejuni-specific IgG antibodies increased with age, from 20.6% in the 15–34 years age group to 32.4% in the 50 – 69 years age group. Humans are likely to be exposed to Campylobacter a number of times during their lifetime, resulting in immune responses that can last several years [8]. Further, as the types/strains of Campylobacter are diverse, it is probable that people are more likely to develop immune protection to the more common types to which they are exposed. Hence we hypothesise that the general population develops increased immunity to the more common types of Campylobacter as they grow older. Here we test this hypothesis by analysing a large dataset of Penner serotyped cases of human campylobacteriosis, stratified by age, to determine if the prevalence of common serotypes decreases with the age of the population.

Methods

Data were collated from the Grampian NHS trust reporting human infections of C. jejuni in Grampian, Scotland (approximately 2300 cases during 1997 – 1999). These data included each patient's age, gender and date of infection. Isolate serotyping had been performed on these cases, using the Penner method [9]. Cases with no recorded age (105), as well as untyped and C. coli cases (168), were omitted from the data set, leaving 1955 typed cases of C. jejuni. The C. jejuni cases were separated into 48 Penner serotypes, which were then collected together into recognised groupings, such as HS:1,44, HS:6,7, and HS:4 complex (comprising serotypes HS:4, 13, 16, 43, 50) [10]. The prevalence of each serotype was determined, with serotypes accounting for more than 10% of the cases being defined as common, and those accounting for less than 10% being classed as uncommon. These data were stratified by age (five year age groups), then ratios of uncommon to common types were determined. The incidence (cases per 100,000) of each age group was calculated, using the population data from the 2001 Scottish Census [11]. Finally χ2 tests were used to test the statistical significance of differences between age group ratios.

Results

The overall incidence of Campylobacter infection by five-year age groups (Figure 1A) shows a large number of cases in the 0–4 years age group (241 cases per 100,000). There is a drop off, before a second peak found in the 25–29 years age group (205 cases per 100,000). From 30 years of age onwards there is a gradual reduction in cases down to the minimum of less than 60 cases per 100,000 among the patients 75 years and older.
Figure 1

. Human campylobacteriosis in Grampian Scotland (1997–1999). a) Incidence of reported cases and b) Ratio of uncommon to common serotypes.

. Human campylobacteriosis in Grampian Scotland (1997–1999). a) Incidence of reported cases and b) Ratio of uncommon to common serotypes. The most prevalent Penner serotypes found in these data were HS:4 complex, HS:2, and HS:1,44 (427, 420, and 205 cases respectively) which account for a total of 53.8% of all tested cases (Table 1). These three type groups were classified as common, for comparison against the 40 other uncommon serotypes.
Table 1

C. jejuni Serotypes Number of reported cases of C. jejuni for Grampian, Scotland (1997–1999) by Penner serotypes, including separation into groups less than and greater than 40 years of age.

Penner SerotypeTotal (%)Age
<40 (%)>40 (%)
4 complexa427 (21.8)286 (23.8)141 (18.7)
2420 (21.5)285 (23.8)135 (17.9)
1,44205 (10.5)130 (10.8)75 (9.9)
11128 (6.5)55 (4.6)73 (9.7)
6,7113 (5.8)67 (5.6)46 (6.1)
845 (2.3)18 (1.5)27 (3.6)
2344 (2.3)25 (2.1)19 (2.5)
2127 (1.4)16 (1.3)11 (4.5)
526 (1.3)17 (1.4)9 (1.2)
923 (1.2)14 (1.2)9 (1.2)
3723 (1.2)10 (0.8)13 (1.7)
Otherb474 (24.2)277 (23.1)197 (26.1)
Total19551200755

aSerotypes 4, 13, 16, 43, 50

b Types accounting for less than 1% of total.

C. jejuni Serotypes Number of reported cases of C. jejuni for Grampian, Scotland (1997–1999) by Penner serotypes, including separation into groups less than and greater than 40 years of age. aSerotypes 4, 13, 16, 43, 50 b Types accounting for less than 1% of total. The ratios of uncommon to common types by five-year age groups (Figure 1B) show that for ages 0 – 39 there is a consistently greater number of infections from the common types (HS:4 complex, HS:2, HS:1,44), with an uncommon/common mean ratio of 0.71 (± 0.10). For patients aged 40 years and older, all age groups but one (45–49 years) have a higher incidence of uncommon types (mean: 1.20 ± 0.18). A χ2 test confirms that the difference is highly statistically significant (p < 0.001).

Discussion

In this study we compiled the Penner serotype data for nearly 2000 cases of human Campylobacter jejuni infections in Grampian, Scotland, determined which were the common types, and identified that these types are significantly more prevalent in younger age groups (less than approximately 40 years). The reduced frequency of common types in older age groups, along with a general reduction in incidence of infection, provides evidence for the hypothesis that people develop immunity to the most common types of C. jejuni during their lifetimes. From the age-specific incidence data (Figure 1A) it is clear that the highest incidence occurs in the 0–4 years age group, which agrees with previous studies [12]. This could be due to many factors including lack of immunity, higher rates of reporting in the age group, or a higher risk of exposure to a particular infection pathway. For example, in rural regions such as Grampian, Scotland, where farm animals shed high loads into the environment, small children may have a high likelihood of coming into contact with, and ingesting, the bacteria. The reduction of incidence in the 5–9 and again in the 10–14 age groups is similar to previous studies [13], which may be due to improved hygiene reducing the risk of environmental exposure. This trend then reverses with a sharp increase in incidence in the older teens/early twenties. This occurs around the age when people are more likely to be travelling and hence coming into contact with new strains. Case-control studies have found that international and national travel is an important risk factor for infection [14]. In humans >30 years, a gradual reduction in incidence is observed. This, taken together with the results of the Danish study [7] showing that seroprevalence increases with age, and the fact that it has been demonstrated that elevated levels of Campylobacter jejuni immunoglobulin A reduces the risk of Campylobacter diarrhoea in adults traveling to Thailand [15], suggests that immunity may be causing protection from Campylobacter infection, or at least symptomatic infection. However, the lower incidence could also be caused by reduced exposure to the infection pathways more common in younger age groups. The common serotypes found in these data (Table 1) are consistent with those found in previous studies [16,17], which are also the same types found in poultry and farm animals [17]. Although we do not have the epidemiological data to ascertain whether the human cases can be attributed to animals/poultry it is clear that the majority of cases in all age groups below 40 are from these common serotypes (Figure 1B).

Conclusion

These data presented here demonstrate lower incidence along with the reduced occurrence of infection from the common serotypes with age, supporting the hypothesis of increased immunoprotection in the population with age. However, it is possible that changing exposure to Campyolobacter with age would confound our results, which can only be clarified by performing a comprehensive epidemiological age-stratified exposure assessment.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

GM collected the data, performed the analysis, and drafted the manuscript. GMD participated in the design of the study and helped draft the manuscript. TMSR carried out the serotyping and helped collect the data. IDO participated in the design of the study and helped in the interpretation of the data. NJCS conceived of the study, coordinated it, and assisted with the statistical analysis.

Pre-publication history

The pre-publication history for this paper can be accessed here:
  14 in total

1.  Foreign and domestic travel and the risk of Campylobacter infection: results from a population-based sentinel surveillance scheme.

Authors: 
Journal:  J Travel Med       Date:  2003 Mar-Apr       Impact factor: 8.490

2.  Distribution of serotypes of Campylobacter jejuni and C. coli from Danish patients, poultry, cattle and swine.

Authors:  E M Nielsen; J Engberg; M Madsen
Journal:  FEMS Immunol Med Microbiol       Date:  1997-09

3.  Pre-exposure anti-Campylobacter jejuni immunoglobulin a levels associated with reduced risk of Campylobacter diarrhea in adults traveling to Thailand.

Authors:  S E Walz; S Baqar; H J Beecham; P Echeverria; C Lebron; M McCarthy; R Kuschner; S Bowling; A L Bourgeois; D A Scott
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

4.  Antibody responses to Campylobacter infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients.

Authors:  M A Strid; J Engberg; L B Larsen; K Begtrup; K Mølbak; K A Krogfelt
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

5.  Passive hemagglutination technique for serotyping Campylobacter fetus subsp. jejuni on the basis of soluble heat-stable antigens.

Authors:  J L Penner; J N Hennessy
Journal:  J Clin Microbiol       Date:  1980-12       Impact factor: 5.948

6.  Long-term antibody responses following human infection with Campylobacter jejuni.

Authors:  S A Cawthraw; R A Feldman; A R Sayers; D G Newell
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

7.  Antibodies, directed towards Campylobacter jejuni antigens, in sera from poultry abattoir workers.

Authors:  S A Cawthraw; L Lind; B Kaijser; D G Newell
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

8.  Phenotypic diversity of Campylobacter isolates from sporadic cases of human enteritis in the UK.

Authors:  D R A Wareing; F J Bolton; A J Fox; P A Wright; D L A Greenway
Journal:  J Appl Microbiol       Date:  2002       Impact factor: 3.772

9.  Campylobacter infection in urban and rural populations in Scotland.

Authors:  C J Sibbald; J C Sharp
Journal:  J Hyg (Lond)       Date:  1985-08

10.  A case-case comparison of Campylobacter coli and Campylobacter jejuni infection: a tool for generating hypotheses.

Authors:  Iain A Gillespie; Sarah J O'Brien; Jennifer A Frost; Goutam K Adak; Peter Horby; Anthony V Swan; Michael J Painter; Keith R Neal
Journal:  Emerg Infect Dis       Date:  2002-09       Impact factor: 6.883

View more
  12 in total

1.  Molecular epidemiology of human Campylobacter jejuni shows association between seasonal and international patterns of disease.

Authors:  N D McCarthy; I A Gillespie; A J Lawson; J Richardson; K R Neal; P R Hawtin; M C J Maiden; S J O'Brien
Journal:  Epidemiol Infect       Date:  2012-02-28       Impact factor: 2.451

2.  Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

Authors:  David R Tribble; Shahida Baqar; Daniel A Scott; Michael L Oplinger; Fernando Trespalacios; David Rollins; Richard I Walker; John D Clements; Steven Walz; Paul Gibbs; Edward F Burg; Anthony P Moran; Lisa Applebee; A Louis Bourgeois
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

Review 3.  Host-pathogen interactions in Campylobacter infections: the host perspective.

Authors:  Riny Janssen; Karen A Krogfelt; Shaun A Cawthraw; Wilfrid van Pelt; Jaap A Wagenaar; Robert J Owen
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

4.  Has retail chicken played a role in the decline of human campylobacteriosis?

Authors:  Fraser J Gormley; Marion Macrae; Ken J Forbes; Iain D Ogden; John F Dallas; Norval J C Strachan
Journal:  Appl Environ Microbiol       Date:  2007-12-07       Impact factor: 4.792

5.  Epidemiology of Campylobacter Infections among Children in Egypt.

Authors:  Rebecca Sainato; Atef ElGendy; Frédéric Poly; Janelle Kuroiwa; Patricia Guerry; Mark S Riddle; Chad K Porter
Journal:  Am J Trop Med Hyg       Date:  2017-12-14       Impact factor: 2.345

6.  Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni.

Authors:  Mario A Monteiro; Shahida Baqar; Eric R Hall; Yu-Han Chen; Chad K Porter; David E Bentzel; Lisa Applebee; Patricia Guerry
Journal:  Infect Immun       Date:  2008-12-29       Impact factor: 3.441

7.  Campylobacter immunity and coinfection following a large outbreak in a farming community.

Authors:  K J Forbes; F J Gormley; J F Dallas; O Labovitiadi; M MacRae; R J Owen; J Richardson; N J C Strachan; J M Cowden; I D Ogden; C C McGuigan
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

8.  Do patients with recurrent episodes of campylobacteriosis differ from those with a single disease event?

Authors:  Julie Arsenault; André Ravel; Pascal Michel; Olaf Berke; Pierre Gosselin
Journal:  BMC Public Health       Date:  2011-01-12       Impact factor: 3.295

9.  Campylobacteriosis in returning travellers and potential secondary transmission of exotic strains.

Authors:  L Mughini-Gras; J H Smid; J A Wagenaar; A DE Boer; A H Havelaar; I H M Friesema; N P French; C Graziani; L Busani; W Van Pelt
Journal:  Epidemiol Infect       Date:  2013-08-20       Impact factor: 4.434

10.  A population-based exposure assessment of risk factors associated with gastrointestinal pathogens: a Campylobacter study.

Authors:  L A MacRitchie; C J Hunter; N J C Strachan
Journal:  Epidemiol Infect       Date:  2012-08-09       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.